{"success":true,"data":{"pressRelease":{"id":"170022","rtpr_id":"nGNX33S73v-20261015","ticker":"LGND","exchange":"NASDAQ","all_tickers":["LGND"],"title":"Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026","author":"Globe Newswire","published_at":"2026-10-15T11:00:00.744Z","article_body":"JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals\nIncorporated (Nasdaq: LGND) today announced that it will report third quarter\n2026 financial results on Thursday, October 29, 2026. The company will hold a\nconference call beginning at 8:30 a.m. Eastern time to discuss the results and\nprovide a general business update.\n\n Conference Call and Webcast Information                                                                                                                         \n                                                                                                                                                                 \n Date:             Thursday, October 29, 2026                                                                                                                    \n                                                                                                                                                                 \n Time:             8:30 a.m. Eastern time                                                                                                                        \n                                                                                                                                                                 \n Conference Call:  United States (Local): +1 (585) 542-9983                                                                                                      \n                   United States (Toll-Free): +1 (833) 461-5787                                                                                                  \n                   International: Global Dial-in Numbers (https://help.events.q4inc.com/eahc/international-dial-in-numbers)                                      \n                   Meeting ID: 708822080                                                                                                                         \n                                                                                                                                                                 \n Webcast:          Live and replay webcasts of the call are available here (https://investor.ligand.com/news-and-events/events-and-presentations/default.aspx).  \n\nAbout Ligand\nLigand is a leading royalty aggregator, partnering with biopharmaceutical\ncompanies to finance and advance late-stage clinical development programs.\nLigand owns and manages one of the largest and most diversified portfolios of\nbiopharmaceutical royalties in the industry, with economic interests in more\nthan 200 development and commercial-stage assets. Ligand funds high-value\nprograms in exchange for long-term economic interests, aligning capital with\nclinical and commercial success. Ligand’s royalty portfolio is designed to\ndeliver consistent and predictable revenue streams across a broad range of\ntherapeutic assets. Ligand also licenses its proprietary technologies,\nCaptisol® and NITRICIL™, to support drug development and formulation across\nits global partner network. For more information, visit www.ligand.com or\nfollow Ligand on X\n(https://www.globenewswire.com/Tracker?data=ou1T3n7eZKg1e9pVdmnJ50fMYCXUwB0F3Yu9oB7QyYXj6P_IBD0UkX5rgdPo0lNve-29-cxvzf5r4jE9T7Nk2Q==)\nand LinkedIn\n(https://www.globenewswire.com/Tracker?data=IyktccKQHbuo-8CjIjOtsoIHpwPZwmXzDUZ4tmGmmOJ8-diGeiUGLHLzVxKJzsZaHTLnATzdD_u8OY-IwryIUVjWBZE_FdnRIUdyyHJpfWqPJEs_stBHuk5PoEUMRU8e).\n\nContacts\n\nInvestors:\nMelanie Herman\ninvestors@ligand.com \n(858) 550-7761\n\nMedia:         \nKellie Walsh\nmedia@ligand.com\n(914) 315-6072\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1fe91aa2-494e-4b30-89e8-cad771bbaabf)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX33S73v-20261015","title":"Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026","author":"Globe Newswire","ticker":"LGND","created":"2026-10-15T11:00:00.744Z","tickers":["LGND"],"exchange":"NASDAQ","article_body":"JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals\nIncorporated (Nasdaq: LGND) today announced that it will report third quarter\n2026 financial results on Thursday, October 29, 2026. The company will hold a\nconference call beginning at 8:30 a.m. Eastern time to discuss the results and\nprovide a general business update.\n\n Conference Call and Webcast Information                                                                                                                         \n                                                                                                                                                                 \n Date:             Thursday, October 29, 2026                                                                                                                    \n                                                                                                                                                                 \n Time:             8:30 a.m. Eastern time                                                                                                                        \n                                                                                                                                                                 \n Conference Call:  United States (Local): +1 (585) 542-9983                                                                                                      \n                   United States (Toll-Free): +1 (833) 461-5787                                                                                                  \n                   International: Global Dial-in Numbers (https://help.events.q4inc.com/eahc/international-dial-in-numbers)                                      \n                   Meeting ID: 708822080                                                                                                                         \n                                                                                                                                                                 \n Webcast:          Live and replay webcasts of the call are available here (https://investor.ligand.com/news-and-events/events-and-presentations/default.aspx).  \n\nAbout Ligand\nLigand is a leading royalty aggregator, partnering with biopharmaceutical\ncompanies to finance and advance late-stage clinical development programs.\nLigand owns and manages one of the largest and most diversified portfolios of\nbiopharmaceutical royalties in the industry, with economic interests in more\nthan 200 development and commercial-stage assets. Ligand funds high-value\nprograms in exchange for long-term economic interests, aligning capital with\nclinical and commercial success. Ligand’s royalty portfolio is designed to\ndeliver consistent and predictable revenue streams across a broad range of\ntherapeutic assets. Ligand also licenses its proprietary technologies,\nCaptisol® and NITRICIL™, to support drug development and formulation across\nits global partner network. For more information, visit www.ligand.com or\nfollow Ligand on X\n(https://www.globenewswire.com/Tracker?data=ou1T3n7eZKg1e9pVdmnJ50fMYCXUwB0F3Yu9oB7QyYXj6P_IBD0UkX5rgdPo0lNve-29-cxvzf5r4jE9T7Nk2Q==)\nand LinkedIn\n(https://www.globenewswire.com/Tracker?data=IyktccKQHbuo-8CjIjOtsoIHpwPZwmXzDUZ4tmGmmOJ8-diGeiUGLHLzVxKJzsZaHTLnATzdD_u8OY-IwryIUVjWBZE_FdnRIUdyyHJpfWqPJEs_stBHuk5PoEUMRU8e).\n\nContacts\n\nInvestors:\nMelanie Herman\ninvestors@ligand.com \n(858) 550-7761\n\nMedia:         \nKellie Walsh\nmedia@ligand.com\n(914) 315-6072\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1fe91aa2-494e-4b30-89e8-cad771bbaabf)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-15T11:00:00.782314259Z","server_sent_at_ms":1792062000782},"received_at":"2026-10-15T11:00:00.832Z","source_url":null},"analysis":{"id":"158230","press_release_id":"170022","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Ligand Pharmaceuticals announced it will report third quarter 2026 financial results on Thursday, October 29, 2026.\n\nA conference call to discuss the results and provide a general business update begins at 8:30 a.m. Eastern time, with live and replay webcasts available on the company's investor relations site.\n\nThis is a scheduling notice only; no results or guidance were disclosed.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Calendar item — mark Q3 2026 earnings date for LGND on October 29."},"keyFigures":{},"namedEntities":{"people":[{"name":"Melanie Herman","role":"Investor relations contact"},{"name":"Kellie Walsh","role":"Media contact"}],"products":["Captisol","NITRICIL"],"companies":[{"name":"Ligand Pharmaceuticals Incorporated","ticker":"LGND"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is an earnings-date announcement with no results or figures — a scheduling notice only."},"tickerRelevance":{"others":[],"primary":"LGND"},"globalImportance":5,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"earnings-date-notice","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Ligand Pharmaceuticals announced it will report third quarter 2026 financial results on Thursday, October 29, 2026.\n\nA conference call to discuss the results and provide a general business update begins at 8:30 a.m. Eastern time, with live and replay webcasts available on the company's investor relations site.\n\nThis is a scheduling notice only; no results or guidance were disclosed.","key_figures":{},"named_entities":{"people":[{"name":"Melanie Herman","role":"Investor relations contact"},{"name":"Kellie Walsh","role":"Media contact"}],"products":["Captisol","NITRICIL"],"companies":[{"name":"Ligand Pharmaceuticals Incorporated","ticker":"LGND"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-15T11:00:08.254Z","global_importance":5,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap","eventGravity":"earnings-date-notice","issuerAuthored":true}},"durationMs":3659,"modelName":"glm-5.3-flashx"}}